BioSpace News Archive

Leading Specialty Distributor Introduces Quality and Regulatory Consultancy Service for Healthcare Partners.

Enteris BioPharma, Inc. , a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced today an abstract has been accepted for an oral presentation at the ASRM 2022 Scientific Congress & Expo.

PsiloTec Health Solutions Inc. is pleased to announce the filing of the Company’s third provisional patent application with the United States Patent and Trademark Office.

PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will release its second quarter 2022 financial results on Thursday, August 4, 2022 at 6:00 a.m. ET.

Biotricity Inc. today announced its financial results for its fiscal 2022 fourth quarter and year ended March 31, 2022.

Stimdia Medical, Inc., an emerging leader in the development of neurostimulation technology intended to strengthen and condition the diaphragm in patients on mechanical ventilation, announced the initial closing of $16M, representing the first tranche of a Series B offering totaling $30M.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that data from the CANDLE 304s nested sub-study of ibrexafungerp for prevention of recurrent vulvovaginal candidiasis (RVVC) will be presented during the International Society for the Study of Vulvovaginal Disease (ISSVD) XXVI World Congress and International Vulvovaginal Disease.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Herbert “Skip” Virgin, M.D., Ph.D., Vir’s executive vice president, research and chief scientific officer, will step down effective August 31, 2022 to pursue a new position as chief medical officer and head of the Altos Institute of Medicine.

Altos Labs (Altos) today announced that Herbert “Skip” Virgin, MD, PhD, will join the company as Chief Medical Officer and Head of the Altos Institute.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new two-year data from the TENAYA and LUCERNE studies that reinforce the long-term efficacy, safety and durability of Vabysmo® (faricimab-svoa) in wet, or neovascular, age-related macular degeneration (AMD), a leading cause of vision loss.